Akeso details ivonescimab biliary cancer survival gain at ESMO

· Health · China · Spain

Akeso on Sunday laid out the magnitude of survival improvement from its PD-1xVEGF bispecific ivonescimab in a late-stage, China-only biliary tract cancer study, according to Endpoints News from ESMO in Madrid. The drug is partnered with Summit Therapeutics, and the biliary data is among the company's early efforts to show success beyond the settings where the bispecific first drew attention, with comparisons to Keytruda framing the discussion. Full trial details were presented at the conference.

Why it matters：Extending a PD-1xVEGF bispecific into new tumor types tests whether the mechanism can compete with PD-1 blockbusters beyond lung cancer.

Key points

  • The study was a late-stage trial conducted only in China.
  • Ivonescimab is a PD-1xVEGF bispecific developed with Summit Therapeutics.
  • The data was presented at ESMO in Madrid.

Sources (original reporting)

More stories from this day